Nuvalent · pitchdeck
Nuvalent | Investor Presentation Deck | 52 slides
52 pages · 4 arc beats · 2 loops
Nuvalent | Investor Presentation Deck | 52 slides
Nuvalent · 2023-10 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
1246810121416182022242628303234363840424446485052
Deck intelligence map
4 coverage by narrative range · generated from this deck JSON
Narrative range 36 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits — 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits — 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides — 0/1 slides
Market Sizing 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits — 0/1 slides
100% 1/1 slides — 0/1 slides
100% 1/1 slides 100% 1/1 slides Traction 33 slides 100% 33/33 slides 100% 33/33 slides · 157 hits — 0/33 slides
45.5% 15/33 slides · 17 hits 15.2% 5/33 slides 100% 33/33 slides 24.2% 8/33 slides Slide inventory
52 every slide · same image gating as the playbook
03
The slide uses a visual bracket system to connect the core mission statement to three pillars.inspire_vision
05
Includes a grid of headshots for the leadership team and lists for board members and advisors.other
06
Uses a Venn diagram to illustrate the intersection of solving for resistance and selectivity.present_solution
Open slide detailBeat · Solution
07
Uses a before-after-bridge framework to contrast existing therapy failure with Nuvalent's success.frame_problem
08
Uses a visual comparison framework to contrast traditional non-selective kinase inhibitors with the company's selective approach.present_solution
Open slide detailLoop · Cost Of Inaction
09
The slide uses a list of icons to represent key clinical attributes of the drug candidate.present_solution
Open slide detailLoop · Cost Of Inaction
10
The table segments patients into kinase inhibitor naïve and those with 1 prior inhibitor, further sub-segmented by mutation type (G2032R vs Non-G2032R).size_opportunity
11
The table uses a green/white color coding to highlight positive attributes of NVL-520 compared to competitors.compare_peers
Open slide detailLoop · Cost Of Inaction
12
The slide uses a medical illustration to map specific TRK receptor inhibition side effects to anatomical locations.frame_problem
Open slide detailLoop · Cost Of Inaction
13
The slide uses dot plots to show IC50 values for different drugs across fusion partners and mutations, and a bar chart to show tumor regression efficacy.show_traction
14
The chart on the right uses a log scale for the y-axis to visualize selectivity indices.present_solution
15
The slide uses a side-by-side comparison framework to delineate the two phases of the clinical trial.plan_implementation
16
The slide details the patient population (N=35) and the subset of response-evaluable patients (N=21) across five dose cohorts.analyze_data
17
The data highlights a heavily pretreated population, with 77% having received 3 or more prior lines of therapy.analyze_data
18
Data as of 13 Sep 22. N=35 patients.analyze_data
19
The chart displays dose-dependent exposure over 24 hours, with horizontal dashed lines representing efficacy targets for different ROS1 variants in CNS and perishow_traction
20
Clinical trial data table showing efficacy metrics for NVL-520.analyze_data
21
Clinical trial data visualization (waterfall plot) with patient-level characteristics table below.show_traction
Open slide detailBeat · Traction
22
Swimmer plot showing patient-level treatment duration, response status, and ongoing treatment status.show_traction
Open slide detailBeat · Traction
23
Includes a spider plot (target lesion change) and a bar chart (allele clearance).show_traction
Open slide detailBeat · Traction
24
Includes patient case study with longitudinal MRI scans.show_traction
Open slide detailBeat · Traction
25
The slide uses a timeline-style list on the left to show treatment history and a visual 'before-and-after' comparison of medical imaging on the right.illustrate_case
Open slide detailBeat · Traction
27
Includes clinical trial data cut-offs and patient enrollment numbers.show_traction
Open slide detailBeat · Traction
28
The slide details specific patient cohorts (2a-2e) with varying treatment histories and trial objectives.show_traction
Open slide detailBeat · Traction
30
The table highlights the clinical challenge of resistance mutations and CNS involvement across different treatment lines.size_opportunity
Open slide detailBeat · Traction
31
The table uses a green/white color coding to indicate positive vs negative results for specific ALK-related activities.compare_peers
Open slide detailBeat · Traction
32
The slide uses a split-panel layout to contrast in vitro IC50 data with in vivo tumor regression data.show_traction
Open slide detailBeat · Traction
33
The slide uses a bar chart for brain penetrance and a scatter plot for selectivity index to demonstrate the drug's therapeutic profile.present_solution
Open slide detailBeat · Traction
34
The slide outlines the study design for NVL-655, detailing patient population, objectives, and cohort stratification.present_framework
Open slide detailBeat · Traction
35
The slide uses a process flow diagram to illustrate patient enrollment and expansion cohorts.analyze_data
Open slide detailBeat · Traction
37
Data cut-off: 8 Aug 2023. Includes specific footnotes regarding dose modifications and discontinuations.analyze_data
Open slide detailBeat · Traction
38
The chart demonstrates dose-proportional exposure and confirms that doses >= 50 mg QD exceed efficacy thresholds for various ALK mutations in the CNS.analyze_data
Open slide detailBeat · Traction
39
The chart displays patient-level data categorized by dose (15mg to 200mg) and mutation type, highlighting the efficacy of the drug in clearing specific ALK mutashow_traction
Open slide detailBeat · Traction
40
The slide presents clinical trial data for NVL-655, showing efficacy across different resistance mutation profiles and prior treatment histories.show_traction
Open slide detailBeat · Traction
41
Clinical trial data visualization showing ORR and best percentage change in target lesions.show_traction
Open slide detailBeat · Traction
42
The chart is a swimmer plot, a standard visualization in oncology clinical trials to show time-to-event data for individual patients.show_traction
Open slide detailBeat · Traction
43
Includes two patient case studies with MRI scans showing tumor reduction.show_traction
Open slide detailBeat · Traction
44
Includes clinical data points for EML4-ALK v3, G1202R, G1269A, and I1322M.illustrate_case
Open slide detailBeat · Traction
45
The slide uses a hierarchical bulleted list to summarize clinical trial conclusions.summarize
Open slide detailBeat · Traction
46
The slide uses a clear, icon-based list to define the therapeutic profile.present_solution
47
The slide uses three distinct chart types to demonstrate the drug's competitive advantage in a preclinical setting.present_solution
49
The slide uses a hexagonal process flow to illustrate the company's strategic methodology.present_framework
50
The slide uses a Gantt-style visualization to represent clinical trial progress.plan_implementation